T2 Biosystems, Inc.

Astra Ab

Avant Immunotherapeutics, Inc.

T Cell Sciences, Inc.

T Cell Diagnostics, Inc.

Charles William Rittershaus

Patrick C Kung

Mark John Audeh

Parris S Wellman

Vasiliki Demas

Wei-Tao Tian

Stephen H Ip

Thomas Jay Lowery, Jr

Lori Anne Neely

Matthew Blanco

James Franklin Chepin

Adam Suchocki

Marilyn Lee Fritzemeier

Robert V Skibbens

Larry D Henry

Michael Min

Nancy L Wood

Mary Ellen Snider

Jone-Long Ko

Hwa-Tang Wang

Carol A Toth

Rahul K Dhanda

Lawrence J Thomas

George Henry Parsons

Alfred E Fox

Alison Skelley

Nancy Jones

Sonia Kumar

Daniella Lynn Plourde

John J McDonough

Isaac Koh

Thomas Jay Lowery

Rahul Dhanda

Brian Mozeleski

Patricia S Meisner

The present invention relates to containers for holding liquid samples. The containers may be useful for mixing a liquid sample or lysing cells in a liquid sample. The invention also relates to methods of using the containers of the invention.

Containers for agitation of liquid samples and methods of use thereof

This invention features devices and methods for analyte processing and detection, and use of such methods, e.g., in the treatment and diagnosis of disease or determining the presence of a pathogen.

Conduit-containing devices and methods for analyte processing and detection

This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.

NMR systems and methods for the rapid detection of analytes

Tube cap

Finned tube

This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.

Modulation of cholesteryl ester transfer protein (CETP) activity

Conjugates are disclosed comprising a broad range helper T cell epitope portion and a B cell epitope portion from a cholesteryl ester transfer protein (CETP), which conjugates are capable of eliciting an immune response in an individual against the individual's endogenous CETP activity. The conjugates are useful in methods to inhibit CETP activity, to raise serum levels of high density lipoproteins, and to prevent or treat cardiovascular disease, such as atherosclerosis.

The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intercellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.

Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed &agr;F1 and &agr;F2, which react with two different epitopes on the framework region of the &agr; monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with &bgr; chain variable regions V&bgr;5.3 and V&bgr;8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody &dgr;TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

Monoclonal antibodies reactive with defined regions of the T cell antigen receptor

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

Monoclonal antibodies reactive with defined regions of the T cell

Growing community of inventors

Malden, MA, United States of America

Charles William Rittershaus